Weight Loss Drugs: Pills Arrive as Retatrutide and CagriSema Loom

A crowded field gets more crowded

Earlier this year, "14 new weight-loss drugs on the horizon" was a fair summary of the obesity pipeline. By October 2026 it undercounts it. Several drugs on those early lists have now been approved, some candidates have stalled, and the main question has changed. Investors and patients used to ask whether another GLP-1 drug would reach the market. Now they are asking which formats, prices and extra benefits will set the leaders apart. GoodRx's April roundup counted 13 FDA-approved weight-loss medications. It tracked candidates including aleniglipron, retatrutide, survodutide and Pfizer's PF-08653944, and it noted that Aardvark Therapeutics had paused its oral obesity trials during a safety review.11 More recent trackers count at least ten obesity programs in Phase 3.17 One industry analysis says more than 200 companies are developing next-generation therapies.15

The latest news fits that pattern. On October 16 a European Medicines Agency advisory committee recommended approving Eli Lilly's Foundayo (orforglipron) for weight management and type 2 diabetes. That moves the pill toward a European launch six months after its U.S. approval. The European Commission usually makes a final decision within 67 days, so approval could come around late December.45

The FDA's fast lane

Foundayo's U.S. approval on April 1 showed how quickly regulators can now move. The drug was the first new molecular entity, and the fifth product overall, cleared under the FDA Commissioner's National Priority Voucher pilot. Approval came 50 days after Lilly filed, nearly 300 days ahead of the standard target date.6 Coverage agrees that it is the first small-molecule GLP-1 drug approved for obesity.4 Unlike Novo Nordisk's Wegovy pill, it can be taken at any time of day without food or water restrictions.9 The same voucher program cleared high-dose Wegovy HD (7.2 mg) on March 19.16

Reports describe Foundayo's effectiveness differently. Lilly's headline figure is 12.4% average weight loss on the highest dose among people who stayed on treatment. Counting everyone randomized, including those who stopped, the figure is 11.1%.1 Pharmacy Times reported ATTAIN-1 results of 7.5% to 11.2% depending on dose.3 One clinical outlet noted that full peer-reviewed results had not yet been widely published by late summer.7 The spread comes from different statistical methods, not conflicting data. Still, readers comparing pills should note that the Wegovy pill's reported 13.6% beats Foundayo on raw weight loss, while Foundayo wins on convenience.8

The efficacy bar keeps rising

The pills now on the market are the convenience tier. The next wave of injectables is aiming much higher. Lilly's retatrutide, which targets three hormones (GIP, GLP-1 and glucagon), produced 28.3% average weight loss at 80 weeks in the TRIUMPH-1 trial on its top dose, and up to 30.3% at 104 weeks in an extension study.16 Lilly plans to file in the U.S. by the first quarter of 2027.14 Results were weaker in people with type 2 diabetes (up to 20.8%) or cardiovascular disease (up to 22.6%).16 An earlier meta-analysis found retatrutide also caused the most side effects among GLP-1-based treatments.11

Novo's CagriSema is the next pending FDA decision, expected in the fourth quarter of 2026.17 Its approval case is weaker than the company would like. Head-to-head against tirzepatide, CagriSema produced 23.0% weight loss versus 25.5% and missed its primary non-inferiority goal.16 Other trackers report that comparison from a different trial readout as 20.2% versus 23.6%, but every account agrees that tirzepatide came out ahead.17

Behind those two, the pipeline is moving past GLP-1 drugs alone:

• Amylin drugs are drawing heavy investment. They include Lilly's eloralintide, Novo's zenagamtide (formerly amycretin) and the Roche/Zealand drug petrelintide, which entered Phase 3 in September.17
• Combinations such as EloraTZP (eloralintide plus tirzepatide) produced up to 23.3% weight loss in a Phase 2 trial in people with type 2 diabetes.18
• Glucagon co-agonists: Boehringer Ingelheim and Zealand's survodutide reported up to 16.6% weight loss in its first Phase 3 readout.14
• More oral drugs are coming. AstraZeneca's elecoglipron and Viking's oral VK2735 are both moving into Phase 3.17
• Muscle preservation: the antibody trevogrumab helped patients on semaglutide keep more lean mass.18

The overall picture is consistent. Novo has narrowed its own pipeline, ending a $285 million deal for a once-monthly obesity drug and dropping other candidates as part of a corporate reset that included renaming itself "Novo."48 Lilly, meanwhile, has about 40 active Phase 3 trials.47

Prices are falling

Prices may be changing patient behavior faster than new science. List prices are still high: about $1,349 a month for Wegovy and roughly $1,086 for Zepbound.24 Few people pay that now. A pricing deal with the White House promised much lower prices through a TrumpRx portal and Medicare coverage with a $50 copay.25 That deal is now reflected in day-to-day pricing. As of mid-October, both GLP-1 pills start at $149 a month for self-pay patients and rise to $299 at higher doses. Zepbound vials from LillyDirect cost $299 to $449.2226 A Medicare GLP-1 Bridge runs from July 2026 through the end of 2027 and offers Wegovy, the Zepbound KwikPen and Foundayo for $50 a month.24

That equal copay has a commercial effect that is easy to miss. Investors say the Medicare bridge removed the price advantage oral Wegovy had at launch.41 When a pill and an injection cost a Medicare patient the same, the more effective drug tends to win. Lilly says injectables still account for about 75% of new starts, and about 80% of patients in the Medicare obesity pilot chose injections.41

Sales: Lilly pulls ahead

The financial results point clearly in one direction. Lilly's second-quarter revenue rose 48% to $23 billion. Mounjaro brought in $9.94 billion and Zepbound $4.93 billion, together almost two-thirds of company revenue.41 Volume grew 60% while realized prices fell 13%, so Lilly is trading lower prices for more patients.41 It raised its 2026 revenue forecast to $85–87 billion.47 Novo's oral Wegovy brought in $497 million in the quarter, slightly below expectations.41 Novo has guided for 2026 sales to fall 5% to 13%.48

Accounts of the pill race differ more than the sales numbers do. Foundayo's first full quarter brought $98 million, just short of estimates.41 Lilly says Foundayo now takes about a third of new U.S. patients starting a GLP-1 pill, and that more than 80% of its users had never taken a GLP-1 drug.44 One count says Novo's pill held about 90% of the oral market early on.44 Another says it still had around 60% of new-patient prescriptions in July.47 My reading is that Novo still leads the oral market by volume, while Lilly leads where it counts most: injectables, profit margins and the pipeline. Lilly's $6.5 billion Houston pill plant suggests it expects demand for oral drugs to grow, even if early sales are modest.44

The cancer question

Cancer research has become an unexpected selling point for this drug class. At ASCO 2026, a Cleveland Clinic analysis of 12,112 patients with stage I–III obesity-related cancers compared GLP-1 drugs with DPP-4 inhibitors, an older class of diabetes medicine. Patients on GLP-1 drugs were 38% to 50% less likely to progress to stage IV in lung, breast, colorectal and liver cancer.40 A Penn study of more than 110,000 women linked GLP-1 use to about 30% lower odds of developing breast cancer.32 An Annals of Oncology analysis reported a hazard ratio of 0.59 for obesity-associated cancers in people with obesity but no diabetes, roughly a 41% lower risk.39

The main caution is also consistent across reports: these studies show correlation, not causation. ASCO's chief medical officer said exactly that.38 Penn's lead researcher called her own work observational and is planning a clinical trial to test the effect directly.37 On safety, a meta-analysis of randomized trials found no increase in gastrointestinal cancers.34 A separate 2026 review found no significant increase in thyroid, pancreatic, breast or kidney cancer, though the uncertainty was wide for some of them.35

What it adds up to

The most likely outlook for 2027 is fewer, stronger leaders rather than 14 equal competitors. Lilly has the most effective approved drug, the most flexible pill and the highest-performing pipeline candidate, so it is best placed to absorb further price cuts. Novo's CagriSema decision this quarter is its best near-term chance to regain ground, but a drug that lost to tirzepatide head-to-head is a weak base for a comeback. Smaller companies will probably compete on new mechanisms, such as amylin drugs, muscle preservation and monthly dosing, rather than on another GLP-1 copy. If randomized trials confirm the cancer findings, that evidence could matter more for insurance coverage than another percentage point of weight loss.